3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
19
Lymphoma
19
Lymphoma, Mantle-Cell
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, B-Cell, Marginal Zone
10
Lymphoma, B-Cell
10
Lymphoma, Non-Hodgkin
9
Recurrence
6
Hodgkin Disease
6
Waldenstrom Macroglobulinemia
5
Neoplasms
3
Multiple Myeloma
3
Leukemia
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Sezary Syndrome
1
Proteostasis Deficiencies
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Interventions
Cyclophosphamide
7
Etoposide
5
Prednisone
4
Doxorubicin
4
Vincristine
3
romidepsin
2
pembrolizumab
2
etoposide phosphate
2
duvelisib
2
Melphalan
2
Brentuximab Vedotin
2
Azacitidine
2
10-propargyl-10-deazaaminopterin
2
tazemetostat
1
sodium-iodide symporter
1
ruxolitinib
1
prednylidene
1
glofitamab
1
fludarabine phosphate
1
fludarabine
1
deltacortene
1
cemiplimab
1
brincidofovir
1
belinostat
1
X-Rays
1
Whole-Body Irradiation
1
Valganciclovir
1
Therapeutics
1
Tacrolimus
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoblastic Lymphadenopathy
×
Bendamustine Hydrochloride
×
1 year
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled